subscribeSubscribe
Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients

Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients
PR NEWSWIRE
04 Apr 2024
Share Share
Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib

Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib
PR NEWSWIRE
04 Jan 2024
Share Share
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance

Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance
PR NEWSWIRE
08 Dec 2023
Share Share
Rigel Announces Presentation of Data from Analysis of REZLIDHIA

Rigel Announces Presentation of Data from Analysis of REZLIDHIA
PR NEWSWIRE
07 Jun 2023
Share Share
Rigel Announces Publication of REZLIDHIA Phase 2 Results in Blood Advances

Rigel Announces Publication of REZLIDHIA Phase 2 Results in Blood Advances
PR NEWSWIRE
02 Feb 2023
Share Share
National Comprehensive Cancer Network Adds REZLIDHIA to Practice Guidelines

National Comprehensive Cancer Network Adds REZLIDHIA to Practice Guidelines
PR NEWSWIRE
18 Jan 2023
Share Share
2022 drug approvals: Biopharma delivered 37 new drugs

2022 drug approvals: Biopharma delivered 37 new drugs
Kevin Dunleavy FIERCE PHARMA
03 Jan 2023
Share Share
Rigel wins US approval of rival drug to Servier leukemia treatment

Rigel wins US approval of rival drug to Servier leukemia treatment
Christopher Newman BIOPHARMADIVE
03 Dec 2022
Share Share
FDA approves Rezlidhia™ for leukaemia

FDA approves Rezlidhia™ for leukaemia
Catherine Eckford EUROPEANPHARMACEUTICALREVIEW
02 Dec 2022
Share Share
U.S. FDA approves Rigel Pharma`s treatment for a type of leukemia

U.S. FDA approves Rigel Pharma`s treatment for a type of leukemia
REUTERS
02 Dec 2022
Share Share